GCGM
MAZE

General Catalyst Group Management’s Maze Therapeutics MAZE Stock Holding History

General Catalyst Group Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9M Hold
1,035,910
– – 16.4% 4
2026
Q1 		$30.9M Hold
1,035,910
– – 16.85% 3
2025
Q4 		$42.9M Hold
1,035,910
– – 19.35% 2
2025
Q3 		$26.9M Hold
1,035,910
– – 0.88% 6
2025
Q2 		$12.7M Hold
1,035,910
– – 0.3% 7
2025
Q1 		$11.4M Buy
+1,035,910
New +$12.5M 1.29% 8

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

General Catalyst Group Management's MAZE Position: Q2 2026 in Review

General Catalyst Group Management held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 1,035,910 shares worth $30.9M. The position accounts for 16.4% of the portfolio, ranked #4.

General Catalyst Group Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $42.9M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • General Catalyst Group Management held 1,035,910 shares of Maze Therapeutics worth $30.9M as of Q2 2026.
  • General Catalyst Group Management left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up 16.4% of General Catalyst Group Management's portfolio in Q2 2026, its #4 holding.
  • General Catalyst Group Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • General Catalyst Group Management's Maze Therapeutics position peaked at $42.9M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.